Komodo Health has announced a new client engagement with Janssen. Janssen Research & Development, LLC (Janssen) will be using Komodo's real-world data and AI software. Janssen plans to use Komodo's services aiming to improve feasibility, site selection and patient recruitment for clinical trials.
The partnership will focus on offering real-time visibility into patient volumes, the ability to identify trial sites, increasing target recruitment, understanding patient cohorts before launch and reaching diverse patient populations. Janssen will utilize Komodo’s Healthcare Map of 325M U.S. de-identified patient journeys, the largest of any health IT company, and Komodo's industry solutions Prism, Sentinel, and Pulse.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.